Daniel Tassé

Daniel Tassé is Chief Executive Officer & Director at DBV Technologies SA since 2019, Director at BioQ Pharma, Inc. since 2014, Lead Independent Non-Executive Director at REGENXBIO, Inc. since 2024, and Director at Roundtable On Critical Care Policy.
Former roles include Chairman, President & Chief Executive Officer at Ikaria, Inc. from 2009 to 2015; Chairman & Chief Executive Officer at Alcresta Therapeutics, Inc. from 2016 to 2018; Director at Biotechnology Innovation Organization from 2011 to 2015; Director at Bellerophon Therapeutics, Inc. from 2014 to 2019; Senior Independent Director at Indivior Ltd. from 2020 to 2021; Vice President & Regional Director-Australasia at GSK Plc in 2004; Director at Pharmaceutical Research & Manufacturers of America from 2011 to 2015; Independent Director at HLS Therapeutics, Inc. from 2018 to 2019; GM-Pharmaceuticals & Technologies Business Unit at Baxter International, Inc. in 2008; Member at Healthcare Leadership Council; and Chief Financial Officer at NRG Energy Ltd. Education includes undergraduate studies at the University of Montréal.